Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;7(2):199-218.
doi: 10.3400/avd.pad.14.01000.

5(th) Asian PAD Workshop

No authors listed

5(th) Asian PAD Workshop

No authors listed. Ann Vasc Dis. 2014.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Tokyo tower was illuminated green on Aged Day in Japan
Fig. 2
Fig. 2
Dual effect of beraprost in PAD
Fig. 1
Fig. 1
Prognosis of CKD by GFR and albuminuria categories (KIDGO 2012)2)
Fig. 2
Fig. 2
Association between eGFR levels and prevalence of PAD8)
Fig. 3
Fig. 3
Incremental correlation between prevalence of abnormal ABI and stage of CKD
Fig. 4
Fig. 4
Relationship of high and low ABI to all-cause and cardiovascular disease mortality in the Strong Heart Study
Fig. 5
Fig. 5
Suggested patient management recommendations
Fig. 6
Fig. 6
PAD patient with concurrent Type 2 DM on insulin therapy (duration of diabetes: 24 years, 65-year-old male) before and after beraprost 120μg/day15)
Fig. 1
Fig. 1
Target cells of PGs2)
Fig. 2
Fig. 2
Effects of beraprost on PAD symptoms: coldness of limbs and numbness5)
Fig. 3
Fig. 3
Effects of beraprost on blood flow in lower limbs: change of ABI5)
Fig. 4
Fig. 4
Improvement of pericutaneous PaO2 with beraprost6)
Fig. 5
Fig. 5
Inhibition of the release of PDGF in vitro8)
Fig. 6
Fig. 6
Proposed action of LDLA13)
Fig. 1
Fig. 1
Causes of ESRD4)
Fig. 2
Fig. 2
Interaction of CKD-MBD in ESRD patients6,7)
Fig. 3
Fig. 3
Mechanisms of vascular calcification in CKD6,7) MGP, matrix GLA protein; OPG, osteoprotegerin
Fig. 4
Fig. 4
Major cause of death5)
Fig. 5
Fig. 5
Hypothetical role of mild to moderate CKD in the occurrence of cardiovascular dysfunction8)
Fig. 6
Fig. 6
Risk of PAD in CKD patients in the ARIC study12)
Fig. 7
Fig. 7
Mortality rate in CKD/PAD patients14)
Fig. 8
Fig. 8
Urine protein excretion and glomerular volume in OLETF rats following beraprost treatment15)
Fig. 1
Fig. 1
Vascular risk in patients with microalbuminuria2)
Fig. 2
Fig. 2
Cardiovascular survival according to the absence vs the presence of microalbuminuria (b) and PAD (b)3)
Fig. 3
Fig. 3
Kaplan-Meier curve for remaining free of PAD by level of eGFR6)
Fig. 4
Fig. 4
Relative risks of future CV events7)
Fig. 5
Fig. 5
Risk of PAD by disease and CRP category8)
Fig. 1
Fig. 1
Percentage of antiplatelet drug-treated patients having ABI <0.914)
Fig. 2
Fig. 2
Changes in SPP. (A) SPP in instep, (B) SPP in sole. ■ indicate group A (beraprost, n=35) and ■ indicate group B (cilostazol or sarpogrelate, n=33).15) *p<0.05, #p<0.01 vs pretreatment values. NS, not significant
Fig. 3
Fig. 3
Effect of treatment on heart rate. ● indicate heart rate of group A (beraprost, n=35), ■ indicate heart rate of cilostazol-treated patients in group B (n=18).15) #p<0.01 vs pretreatment values
Fig. 4
Fig. 4
Pooled survival curves (meta-analysis)17)
See this image and copyright information in PMC

References

    1. 2011 WRITING GROUP MEMBERS; 2005 WRITING COMMITTEE MEMBERS; ACCF/AHA TASK FORCE MEMBERS 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124: 2020-45. - PubMed
    1. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-63 - PubMed
    1. International Society of Nephrology KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Chapter 1: Definition, and classification of CKD. Kidney International Supplements 2013; 3: 19-62 - PMC - PubMed
    1. Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010; 25: 1567-75 - PubMed
    1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654 - PubMed

LinkOut - more resources